Skip to main content

Table 1 Selected demographic and baseline characteristics of the patients

From: Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

Variable Patients
All patients, No. (%) 123 (100)
Sex, No. (%)  
  Female 120 (98)
  Male 3 (2)
Race  
  African American 48 (39)
  Caucasian 5 (4)
  Other 70 (57)
Age (in years) at diagnosis, median [range] 53 [32–78]
Hormone receptor expression status, No. (%)  
  ER+ 81 (66)
  PR+ 67 (54)
  HER2/neu overexpressed 16 (13)
Medical comorbidities, No. (%)  
  DM 20 (16)
  HIV 3 (2)
  Alcohol abuse 5 (4)
  Pre-existing peripheral neuropathy 4 (3)
Taxane received, No (%)  
  Paclitaxel only 46 (37)
  Docetaxel only 70 (57)
  Multiple agents 7 (6)
Total patients needing dose reduction, No. (%) 49 (40)
  CIPN 21 (17)
  Other causes 28 (24)